Target intelligence / Profile preview

Exopolysaccharide Psl of Pseudomonas aeruginosa (Psl)

Target
Psl
Molecular classification
Exopolysaccharide, Biofilm matrix component, Bacterial carbohydrate polymer
01

Overview

Exopolysaccharide Psl is a neutral, branched polysaccharide composed primarily of mannose, rhamnose, and glucose, produced by Pseudomonas aeruginosa through the psl gene locus. Psl is a key structural component of the bacterial biofilm matrix, where it scaffolds cells together, mediates cell–cell and cell–surface adhesion, and provides protection against antimicrobials, host immune effectors, and environmental stresses. Its expression is environmentally regulated and varies between strains, with Psl-dominant and Pel-dominant strains recognized among laboratory and clinical isolates. Psl also plays a role in signaling processes that regulate biofilm gene expression and contributes to the chronicity and resilience of P. aeruginosa infections, particularly in cystic fibrosis airways and on medical devices. Targeting Psl is being explored for novel anti-biofilm therapeutics, but no clinically approved direct inhibitors exist to date.

Other names
Psl polysaccharidePsl exopolysaccharidePolysaccharide synthesis locus exopolysaccharide
02

Mechanism of action

Disruption or inhibition of Psl biosynthesis reduces biofilm integrity and bacterial adherence, making bacteria more susceptible to immune clearance and antibiotics. Surfactant-based or polysaccharide-targeting agents can disrupt the Psl matrix, promoting biofilm dispersion.

03

Biological functions

Biofilm formation and structural scaffoldBacterial adhesion (to surfaces and cells)Protection against antimicrobials and immune responseResistance to environmental stressModulation of inter-bacterial and host interactions
04

Disease associations

Infection (chronic and device-related)Cystic fibrosis lung infectionsAntimicrobial resistanceOther biofilm-associated diseases
05

Safety considerations

Potential for rapid selection of resistance or compensatory polysaccharide expression (e.g., upregulation of Pel or alginate if Psl is inhibited)Disrupting biofilms may cause acute release of bacteria (biofilm dispersion), potentially increasing dissemination and inflammatory response
06

Interacting drugs

There are currently no approved drugs that directly and selectively target Psl, but some experimental inhibitors (e.g., PS80, surfactant-based biofilm inhibitors) have been studied
07

Biomarkers

Psl presence or expression (e.g., psl gene expression) serves as a biomarker for Pseudomonas aeruginosa biofilm formation and can indicate biofilm-related infections, especially in cystic fibrosis patients

Beyond the preview

Go deeper on Exopolysaccharide Psl of Pseudomonas aeruginosa (Psl).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exopolysaccharide Psl of Pseudomonas aeruginosa (Psl).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call